193 related articles for article (PubMed ID: 28782712)
1. Effects of fasudil on pulmonary hypertension in clinical practice.
Zhang Y; Wu S
Pulm Pharmacol Ther; 2017 Oct; 46():54-63. PubMed ID: 28782712
[TBL] [Abstract][Full Text] [Related]
2. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Bei Y; Hua-Huy T; Duong-Quy S; Nguyen VH; Chen W; Nicco C; Batteux F; Dinh-Xuan AT
Pulm Pharmacol Ther; 2013 Dec; 26(6):635-43. PubMed ID: 23928001
[TBL] [Abstract][Full Text] [Related]
4. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
Fujita H; Fukumoto Y; Saji K; Sugimura K; Demachi J; Nawata J; Shimokawa H
Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Raja SG
Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803
[TBL] [Abstract][Full Text] [Related]
6. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
7. The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis.
Abedi F; Omidkhoda N; Arasteh O; Ghavami V; Hosseinzadeh H
Drug Res (Stuttg); 2023 Jan; 73(1):5-16. PubMed ID: 36216340
[TBL] [Abstract][Full Text] [Related]
8. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
Gupta V; Gupta N; Shaik IH; Mehvar R; McMurtry IF; Oka M; Nozik-Grayck E; Komatsu M; Ahsan F
J Control Release; 2013 Apr; 167(2):189-99. PubMed ID: 23353807
[TBL] [Abstract][Full Text] [Related]
9. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Jasińska-Stroschein M; Owczarek J; Łuczak A; Orszulak-Michalak D
Pharmacology; 2013; 91(3-4):178-84. PubMed ID: 23428587
[TBL] [Abstract][Full Text] [Related]
10. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Chen XY; Dun JN; Miao QF; Zhang YJ
Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Tawara S; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Aug; 50(2):195-200. PubMed ID: 17703136
[TBL] [Abstract][Full Text] [Related]
12. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Xiao JW; Zhu XY; Wang QG; Zhang DZ; Cui CS; Zhang P; Chen HY; Meng LL
Circ J; 2015; 79(6):1342-8. PubMed ID: 25797071
[TBL] [Abstract][Full Text] [Related]
14. [Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension].
Sun XZ; Wang DW; Li J
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):946-7. PubMed ID: 17254468
[No Abstract] [Full Text] [Related]
15. Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.
Badejo AM; Dhaliwal JS; Casey DB; Gallen TB; Greco AJ; Kadowitz PJ
Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L828-36. PubMed ID: 18689606
[TBL] [Abstract][Full Text] [Related]
16. Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs.
Lopez NC; Ebensperger G; Herrera EA; Reyes RV; Calaf G; Cabello G; Moraga FA; Beñaldo FA; Diaz M; Parer JT; Llanos AJ
Am J Physiol Regul Integr Comp Physiol; 2016 Jun; 310(11):R1053-63. PubMed ID: 26911462
[TBL] [Abstract][Full Text] [Related]
17. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Li F; Xia W; Yuan S; Sun R
Pediatr Cardiol; 2009 Apr; 30(3):363-6. PubMed ID: 18953591
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
19. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
Fukumoto Y; Matoba T; Ito A; Tanaka H; Kishi T; Hayashidani S; Abe K; Takeshita A; Shimokawa H
Heart; 2005 Mar; 91(3):391-2. PubMed ID: 15710736
[No Abstract] [Full Text] [Related]
20. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
Ishikura K; Yamada N; Ito M; Ota S; Nakamura M; Isaka N; Nakano T
Circ J; 2006 Feb; 70(2):174-8. PubMed ID: 16434811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
